Here, we highlight that the dysfunctions of 6 genes with great potential induce IPAH, and investigational drugs targeting CCL5, CXCR1, CXCR2, CCR1, and ADORA3 may provide a prospective direction for the treatment of IPAH. This evidence concerns the gene CCR1 and idiopathic pulmonary arterial hypertension.